{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:27Z","timestamp":1790255127198,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201261","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:35:02Z","timestamp":1781076902000},"page":"201261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity"],"prefix":"10.1016","volume":"34","author":[{"given":"Frederic","family":"St-Denis-Bissonnette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Mediratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kirkby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stalker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Muradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ardolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-3857","authenticated-orcid":false,"given":"Jessie R.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201261_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jcyt.2016.06.013","article-title":"Expanded and armed natural killer cells for cancer treatment","volume":"18","author":"Shimasaki","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2026.201261_bib3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural Killer Cell Signaling Pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201261_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12387","article-title":"A clinically relevant large-scale biomanufacturing workflow to produce natural killer cells and natural killer cell-derived extracellular vesicles for cancer immunotherapy","volume":"12","author":"St-Denis-Bissonnette","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omton.2026.201261_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omton.2026.201261_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omton.2026.201261_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12938","article-title":"Natural killer cell\u2013derived extracellular vesicles in cancer therapy","volume":"92","author":"Farcas","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/0008-5472.CAN-18-0779","article-title":"Natural Killer\u2013Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms","volume":"79","author":"Neviani","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201261_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1274478","article-title":"IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo","volume":"6","author":"Boieri","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201261_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.10.034","article-title":"Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming","volume":"190\u2013191","author":"Zhu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.omton.2026.201261_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nri.2016.153","article-title":"Programmed cell death and the immune system","volume":"17","author":"Nagata","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cancers14020451","article-title":"Applications of Extracellular Vesicles in Triple-Negative Breast Cancer","volume":"14","author":"St-Denis-Bissonnette","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201261_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201261_bib14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.4049\/jimmunol.1101988","article-title":"Immune surveillance properties of human NK cell-derived exosomes","volume":"189","author":"Lugini","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.70132","article-title":"Ultracentrifugation and Ultrafiltration Differentially Alter the Composition and Functionality of the Biomolecular Corona of Extracellular Vesicles","volume":"5","author":"St-Denis-Bissonnette","year":"2026","journal-title":"J. Extracell. Biol."},{"key":"10.1016\/j.omton.2026.201261_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76319","article-title":"Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses","volume":"11","author":"Dosil","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.omton.2026.201261_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00262","article-title":"Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors","volume":"11","author":"Federici","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","article-title":"Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model","volume":"97","author":"Swift","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201261_bib19","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201261_bib20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201261_bib21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201261_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib23","doi-asserted-by":"crossref","first-page":"13443","DOI":"10.18632\/aging.203109","article-title":"Immunological features beyond CD4\/CD8 ratio values in older individuals","volume":"13","author":"Garrido-Rodr\u00edguez","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.omton.2026.201261_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.166","article-title":"Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell-derived extracellular vesicle-based cancer biotherapeutics","volume":"3","author":"St-Denis-Bissonnette","year":"2024","journal-title":"J. Extracell. Biol."},{"key":"10.1016\/j.omton.2026.201261_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-023-01494-6","article-title":"Advances in single-cell RNA sequencing and its applications in cancer research","volume":"16","author":"Huang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201261_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40779-022-00414-y","article-title":"Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy","volume":"9","author":"Li","year":"2022","journal-title":"Milit. Med. Res."},{"key":"10.1016\/j.omton.2026.201261_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41592-020-0748-5","article-title":"TooManyCells identifies and visualizes relationships of single-cell clades","volume":"17","author":"Schwartz","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omton.2026.201261_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1328094","article-title":"Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases","volume":"14","author":"He","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","article-title":"Immunometabolism and natural killer cell responses","volume":"19","author":"O\u2019Brien","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/biom14080910","article-title":"Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook","volume":"14","author":"Guan","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2026.201261_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1083\/jcb.152.4.835","article-title":"Defective Granule Exocytosis in Rab27a-Deficient Lymphocytes from Ashen Mice","volume":"152","author":"Haddad","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omton.2026.201261_bib33","article-title":"Distinct Role of Rab27a in Granule Movement at the Plasma Membrane and in the Cytosol of NK Cells","volume":"5","author":"Liu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201261_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz7548","article-title":"Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells","volume":"368","author":"Zhou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201261_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1392535","article-title":"Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials","volume":"15","author":"Thompson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.omtn.2023.04.017","article-title":"Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy","volume":"32","author":"McKenzie","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201261_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib39","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1038\/ncomms9306","article-title":"Functional classification of memory CD8+ T cells by CX3CR1 expression","volume":"6","author":"B\u00f6ttcher","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201261_bib40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.immuni.2016.10.018","article-title":"The chemokine receptor CX3CR1 defines three antigen-experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis","volume":"45","author":"Gerlach","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201261_bib41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.immunol.26.021607.090404","article-title":"Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death","volume":"26","author":"Chowdhury","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133920","article-title":"CX3CR1\u2013CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment","volume":"5","author":"Yamauchi","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201261_bib44","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41467-021-21619-0","article-title":"T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors","volume":"12","author":"Yamauchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201261_bib45","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3389\/fimmu.2019.02354","article-title":"The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy","volume":"10","author":"Sun","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.20131601","article-title":"CD160 is essential for NK-mediated IFN-\u03b3 production","volume":"212","author":"Tu","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201261_bib47","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.4049\/jimmunol.2200792","article-title":"CD160 Signaling Is Essential for CD8+ T Cell Memory Formation via Upregulation of 4-1BB","volume":"211","author":"Zhang","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omton.2026.201261_bib49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the Interleukin-10 Receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12645-025-00328-z","article-title":"NK cell-derived artificial extracellular vesicles elicit potent anti-tumor efficacy and tumor microenvironment reprogramming capability","volume":"16","author":"Zhou","year":"2025","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.omton.2026.201261_bib52","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s11426-021-1085-8","article-title":"Natural killer cell-derived extracellular vesicle significantly enhanced adoptive T cell therapy against solid tumors via versatilely immunomodulatory coordination","volume":"64","author":"Nie","year":"2021","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.omton.2026.201261_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12576-020-00776-9","article-title":"NK cell-derived exosomes improved lung injury in mouse model of Pseudomonas aeruginosa lung infection","volume":"70","author":"Jia","year":"2020","journal-title":"J. Physiol. Sci."},{"key":"10.1016\/j.omton.2026.201261_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17534259251355029","article-title":"Biological significance of extracellular vesicles in innate immune system","volume":"31","author":"Jadamba","year":"2025","journal-title":"Innate Immun."},{"key":"10.1016\/j.omton.2026.201261_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CJI.0000000000000179","article-title":"NK Cell\u2013derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells","volume":"40","author":"Shoae-Hassani","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.omton.2026.201261_bib56","article-title":"Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201261_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201261_bib58","article-title":"Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors","volume":"7","author":"Zhang","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201261_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108708","article-title":"SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model","volume":"27","author":"Cummings","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omton.2026.201261_bib60","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nmeth.4185","article-title":"EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research","volume":"14","author":"Van Deun","year":"2017","journal-title":"Nat. Methods"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:37:10Z","timestamp":1790253430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001372"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201261","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201261"}}